InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Not yet recruitingLast updated: 5 April 2024

STRAND STX-001-01: This study is assessing how safe, tolerable and effective a new drug (called STX-001) is on its own and in combination with a standard immunotherapy (Pembrolizumab) in people with advanced solid cancersPh 1/2 Open-label, Multi-center, FIH Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Antitumor Activity of STX-001 Via Intratumoral Injection in Pts w Advanced Solid Tumors as Monotherapy or Combination w Pembrolizumab

Clinical summary

Summary

This study has two phases:

Phase 1 consists of 4 planned dose escalation cohorts of STX-001 delivered as a monotherapy (Cohorts 1m), and 4 planned dose escalation cohorts of STX-001 delivered as a combination therapy, with pembrolizumab treatment given concurrently (Cohorts 1c).

New patients will be enrolled in each dose escalation cohort.

Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple negative breast cancer (TNBC) and melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) will be selected based on analysis of the totality of data from Phase 1.

Conditions

This trial is treating patients with advanced solid cancers

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I/II

Trial Acronym

STRAND STX-001-01

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Strand Therapeutics Inc.

Scientific Title

Ph 1/2 Open-label, Multi-center, FIH Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Antitumor Activity of STX-001 Via Intratumoral Injection in Pts w Advanced Solid Tumors as Monotherapy or Combination w Pembrolizumab

Eligibility

Inclusion

  • ≥ 18 years of age at the time of screening.
  • Mentally competent and able to understand and sign the informed consent form (ICF).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of ≥ 12 weeks per the Investigator.
  • Body weight ˃ 40 kg.
  • At least 4 weeks from any prior major surgery.
  • Willing and able to provide blood samples prior to the start of this study.
  • Has a tumor lesion amenable to injection (must be ≥ 1 cm in diameter and accessible by direct palpation or ultrasound; must not be located adjacent to vital structures, including airways, major nerves, or blood vessels; the lesion for injection) must be accessible for pre and post injection biopsy, and the patient must be willing to consent to biopsy, if deemed safe by the Investigator.
  • Laboratory values (Hematology): Absolute neutrophil count ≥ 1,000 cells/mm3; Platelet count ≥ 75,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL.
  • Laboratory values (Renal): Serum creatinine < 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation
  • Laboratory values (Coagulation): International Normalized Ratio (INR) must be < 1.5 × ULN; Prothrombin time or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless undergoing anticoagulation therapy.
  • Laboratory values (Liver): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 × ULN; Bilirubin ≤ 2 × ULN or ≤ 5 × ULN with liver metastasis.

Phase 1 Inclusion Criteria:

  • Histologically or cytologically documented, locally advanced, or metastatic solid tumor.
  • Disease progression confirmed by imaging or other objective evidence after having received standard treatment or patients with refractory solid tumors. Patients must have progressed or are intolerant of at least one line of prior therapy.

Phase 2 Inclusion Criteria (TNBC):

  • Histologically or cytologically documented findings consistent with TNBC not amenable to curative surgery, radiation, or other therapy.
  • Prior treatment (for advanced, metastatic or [neo]adjuvant) should have included a taxane and/or anthracycline-based therapy and, where appropriate, an approved checkpoint inhibitor.
  • Has disease other than the injected lesion that is measurable by RECIST 1.1.

Phase 2 Inclusion Criteria (melanoma):

  • Histologically or cytologically documented findings consistent with advanced melanoma not amenable to curative surgery, radiation, or other therapy. Uveal melanoma is excluded.
  • Patients who are not candidates for or have refused available therapies are also eligible.
  • Received an anti-programmed death-1 (PD-1) / programmed death ligand-1 (PD-L1) inhibitor as monotherapy or in combination with anti-cytotoxic lymphocyte associated protein 4 (CTLA-4) inhibitor and have either primary or secondary checkpoint inhibitor resistance as per Society for Immunotherapy of Cancer (SITC) consensus definition, unless deemed intolerable by the investigator. Patients with BRAF V600E mutant melanoma should have received a BRAF inhibitor as monotherapy or in combination with other targeted agents (mitogen-activated protein kinase [MAPK] kinase [MEK] inhibitors), unless deemed intolerable by the investigator.
  • Has disease other than the injected lesion that is measurable by RECIST 1.1

Exclusion

  • History of autoimmune disease and/or requiring immunosuppression (except hypothyroidism).
  • History of solid organ transplant.
  • Cardiovascular exclusions: Medical history of an arterial thrombotic event, stroke, or transient ischemic attack within the past 12 months; medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a cardiac arrhythmia that required treatment within the past 12 months; medical history of myocardial infarction or unstable angina within 6 months before Cycle 1 Day 1; QTcF prolongation to > 470 ms in women and > 450 ms in men based on a 12-lead electrocardiogram (ECG) in triplicate using the Fridericia formula: QTc = QT / RR1/3.
  • Evidence of active infection requiring intravenous (IV) antibiotics during screening requiring therapy within 7 days prior to Cycle 1 Day 1.
  • Active uncontrolled bleeding, or a bleeding diathesis within 7 days prior to Cycle 1 Day 1.
  • Serious or non-healing wound, fistula, skin ulcer, or non-healing bone fracture within 7 days prior to Cycle 1 Day 1.
  • Known human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
  • Untreated central nervous system tumor, epidural tumor or metastasis, or brain metastasis.
  • Another primary malignancy that has not been treated with curative intent, except for non-metastatic cutaneous basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.
  • Serious illness considered by the Investigator as incompatible with participating in this clinical study.
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results.
  • Prior IL-12 therapy.
  • Receipt of any vaccine within 30 days prior to the first dose of study treatment.
  • Use of another anticancer therapy within 3 weeks prior to Cycle 1 Day 1 or 5 half-lives, whichever is shorter.
  • Previously enrolled in this study.
  • Actively enrolled in another clinical study unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study.
  • Known severe hypersensitivity (Grade ≥ 3) to study treatment or any of the excipients of the products.
  • Known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Currently pregnant (confirmed with positive pregnancy test), breast-feeding or planning to become pregnant. For women of childbearing potential (WOCBP), a negative serum beta-human chorionic gonadotropin (β-HCG) result must be in place within 72 hours of first treatment dose.
  • Women of childbearing potential not willing to use a highly effective method of contraception.
  • Unwilling or unable to follow protocol requirements.

Inclusion

  • You have had treatment, but your cancer has come back.
  • Your cancer has spread to other parts of the body.
  • Your cancer has not spread to other parts of the body.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had a certain type of treatment or surgical procedure.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Not yet recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.